| Clinical outcomes of bivalirudin for ischemic heart disease. | |
| | |
MedLine Citation:
|
PMID: 10562259 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Current treatment strategies for percutaneous coronary revascularization and acute coronary syndromes incorporate thrombin inhibition with either unfractionated or fractionated heparin. The peptide bivalirudin (Hirulog) is a direct thrombin inhibitor whose pharmacological properties differ from those of heparin. We conducted a systematic overview (meta-analysis) to assess the effect of bivalirudin on 4 end points: death, myocardial infarction, major hemorrhage, and the composite of death or infarction. METHODS AND RESULTS: Six trials (5674 patients) represent the randomized, controlled bivalirudin experience, including 4603 patients undergoing elective percutaneous coronary revascularization and 1071 patients with acute coronary syndromes. ORs for the 4 clinical end points were calculated for each trial. Four trials (4973 patients) that compared bivalirudin with heparin were combined with the use of a random-effects model. In these trials, bivalirudin was associated with a significant reduction in the composite of death or infarction (OR 0.73, 95% CI 0.57 to 0.95; P=0.02) at 30 to 50 days, or 14 fewer events per 1000 patients so treated. There also was a significant reduction in major hemorrhage for the same trials (OR 0.41, 95% CI 0. 32 to 0.52; P<0.001, or 58 fewer events per 1000 patients so treated). A similar analysis combined 2 dose-ranging trials (701 patients) that compared therapeutic (activated partial thromboplastin time more than twice the control time) with subtherapeutic bivalirudin anticoagulation (activated partial thromboplastin time less than twice the control time). CONCLUSIONS: Bivalirudin is at least as effective as heparin, with clearly superior safety. Thus, it provides an unprecedented net clinical benefit over heparin in patients with ischemic heart disease. |
| | |
Authors:
|
D F Kong; E J Topol; J A Bittl; H D White; P Théroux; V Hasselblad; R M Califf |
Related Documents
:
|
18243369 - Intermittent heparin infusion in children with ischemic heart disease caused by kawasak... 16682709 - Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of a... 19147609 - Profile of bleeding and ischaemic complications with bivalirudin and unfractionated hep... 9534319 - Mean-term calcium heparin treatment in acute transmural anterior myocardial infarction:... 10543929 - Activated partial thromboplastin time and clinical outcome after thrombin inhibition in... 18987409 - 'bail-out' bivalirudin use in patients with thrombotic complications unresponsive to co... 16935639 - "stretched loop sign" of the vertebral artery: a predictor of vertebrobasilar insuffici... 21873339 - The effect of cardiac resynchronization therapy on left ventricular diastolic function ... 1913729 - Abdominal aortic aneurysms. |
Publication Detail:
|
Type: Journal Article; Meta-Analysis |
Journal Detail:
|
Title: Circulation Volume: 100 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 1999 Nov |
Date Detail:
|
Created Date: 1999-12-07 Completed Date: 1999-12-07 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 2049-53 Citation Subset: AIM; IM |
Affiliation:
|
Duke Clinical Research Institute, Durham, NC 27715, USA. kong0008@mc.duke.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticoagulants
/
therapeutic use* Biological Markers Drug Administration Schedule Heparin / therapeutic use Hirudin Therapy Hirudins / analogs & derivatives* Humans Myocardial Ischemia / drug therapy* Outcome Assessment (Health Care) Peptide Fragments / therapeutic use* Randomized Controlled Trials as Topic Recombinant Proteins / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Biological Markers; 0/Hirudins; 0/Peptide Fragments; 0/Recombinant Proteins; 128270-60-0/bivalirudin; 9005-49-6/Heparin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: ear...
Next Document: Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study.